Ets‐1 and hypoxia inducible factor‐1α inhibition by angiotensin II type‐1 receptor blockade in hormone‐refractory prostate cancer

Abstract

This study suggests that AT1R blockade may have a significant impact on HRPC through the inhibition of HIF-1alpha and Ets-1 and the resulting suppression of angiogenesis. Our results provide the molecular basis of the clinical benefit of ARB as an angiogenic inhibitor in HRPC.